Mutations as munitions: Neoantigen vaccines get a closer look as cancer treatment.
A Katsnelson - Nature medicine, 2016 - go.gale.com
A Katsnelson
Nature medicine, 2016•go.gale.comIn 2010, the Dendreon company received the news it had been hoping for: the US Food and
Drug Administration had approved its therapeutic cancer vaccine Provenge for prostate
cancer. At the time of Provenge's approval, the headlines hailed it as groundbreaking, and
they noted a surge in the price of Dendreon's stock as the company announced its $93,000
price tag for the therapy. But enthusiasm fizzled when the company later revealed that fewer
people used the therapy than expected, and in November 2014 the company filed for …
Drug Administration had approved its therapeutic cancer vaccine Provenge for prostate
cancer. At the time of Provenge's approval, the headlines hailed it as groundbreaking, and
they noted a surge in the price of Dendreon's stock as the company announced its $93,000
price tag for the therapy. But enthusiasm fizzled when the company later revealed that fewer
people used the therapy than expected, and in November 2014 the company filed for …
In 2010, the Dendreon company received the news it had been hoping for: the US Food and Drug Administration had approved its therapeutic cancer vaccine Provenge for prostate cancer. At the time of Provenge's approval, the headlines hailed it as groundbreaking, and they noted a surge in the price of Dendreon's stock as the company announced its $93,000 price tag for the therapy. But enthusiasm fizzled when the company later revealed that fewer people used the therapy than expected, and in November 2014 the company filed for bankruptcy.
Gale